Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia
crystal710 / Pixabay

Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia

According to a story from PR Newswire, the 60th Annual Meeting of the American Society of Hematology has been generating a lot of press lately as many groundbreaking studies, research,…

Continue Reading Recent Clinical Trials Highlight Potential of Targeted Therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia
Positive Results from Safety Trial of CBD for Refractory Pediatric Epilepsy
Source: pixabay.com

Positive Results from Safety Trial of CBD for Refractory Pediatric Epilepsy

INSYS Therapeutics has just released data from their long-term safety study of CBD as a treatment for refractory pediatric epilepsy. The results were positive and we're excited about the future…

Continue Reading Positive Results from Safety Trial of CBD for Refractory Pediatric Epilepsy

Highlights from RAREfest: Cambridge’s Rare Disease Festival

This weekend Patient Worthy attended RAREfest, an event being held in the UK by the Cambridge Rare Disease Network to raise awareness and promote discussion around rare disease issues. The…

Continue Reading Highlights from RAREfest: Cambridge’s Rare Disease Festival
Experimental Treatment for Sézary Disease Shows Promise in Early Trials
DarkoStojanovic / Pixabay

Experimental Treatment for Sézary Disease Shows Promise in Early Trials

According to a story from globenewswire.com, the biotechnology company Innate Pharma SA recently announced the latest data from a Phase 1 clinical trial of the company's investigational medical product IPH4102.…

Continue Reading Experimental Treatment for Sézary Disease Shows Promise in Early Trials
Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
frolicsomepl / Pixabay

Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy

According to a story from Market Screener, an analysis of real-world data (data gathered outside of the clinical setting) suggests that the drug eltrombopag, marketed as Revolade, offers substantial advantages…

Continue Reading Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
Close Menu